Prosecutors <Anchor> has filed a warrant for arrest for former Chairman Lee Woong-ryul. This is a false charge of fabricating an ingredient of Inbosa, a treatment for osteoarthritis, by falsely reporting it.

Reporter Sohwan-wook.

<Reporter>

Prosecutors who are investigating suspicions surrounding'Invossa', an osteoarthritis treatment agent, have filed a warrant for arrest for former Chairman Lee Woong-ryul.

It's allegedly violating the Pharmacopoeia Act and fraud.

Earlier, the prosecution prosecuted CEO Woo-Seok Lee of Kolon Life Science for seven charges, including violations of the Pharmacist Act and the Capital Market Act.

From November 2017 to March last year, Lee is accused of selling Invossa 2-liquid ingredients that have been approved by the Ministry of Food and Drugs as'chondrocytes' as ingredients that are different from those approved.

Kidney-derived cells can cause tumors and are prohibited for use in the United States and Europe.

Invosa was approved by the Korea Food and Drug Administration as the first gene therapy in Korea in 2017, but for this reason, the permit was finally revoked in July last year.

Prosecutors believe that former President Lee was also involved in the listing fraud.

In 2017, Kolon Tissue Gene, which led the development of an invoicing company, was listed on KOSDAQ, but it is a securities report made of false data submitted to the Food and Drug Administration, which attracted about 200 billion won.

Kolon said the recent situation stemmed from misunderstandings and believes that the misunderstandings will be resolved.